Search
Ifosfamide
go.drugbank.com/drugs/DB01181ApprovedInvestigationalIfosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2A6 SubstratesProducts: IFO-CELL N 1000, IFO-cell N 1000; Solution for Infusion (1000mg per vial)Sparfloxacin
go.drugbank.com/drugs/DB01208ApprovedWithdrawnSparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA top...
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP1A2 InhibitorsCeftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalCeftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges , eyes , and inner ear . Ceftriaxone has broader and strong...
Categories: P-glycoprotein inhibitorsEstazolam
go.drugbank.com/drugs/DB01215ApprovedIllicitInvestigationalA benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesGliquidone
go.drugbank.com/drugs/DB01251ApprovedGliquidone is a sulfonylurea drug used to treat diabetes mellitus type 2. It is an ATP-dependent K+ (KATP) channel blocker. This block causes a depolarization which leads to activation of voltage-dependent Ca channels and Ca2+ influx, an...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesErgometrine
go.drugbank.com/drugs/DB01253ApprovedInvestigationalAn ergot alkaloid with uterine and vascular smooth muscle contractile properties.
Synonyms: N-(α-(hydroxymethyl)ethyl)-D-lysergamide, N-(2-Hydroxy-1-methylethyl)-D-(+)-lysergamideCategories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesLumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnLumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Aust...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesAmobarbital
go.drugbank.com/drugs/DB01351ApprovedIllicitA barbiturate with hypnotic and sedative properties (but not antianxiety). Adverse effects are mainly a consequence of dose-related CNS depression and the risk of dependence with continued use is high. (From Martindale, The Extra Pharmac...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersHexobarbital
go.drugbank.com/drugs/DB01355ExperimentalA barbiturate that is effective as a hypnotic and sedative.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C9 SubstratesRasagiline
go.drugbank.com/drugs/DB01367ApprovedInvestigationalRasagiline is an irreversible inhibitor of monoamine oxidase and is used as a monotherapy in early Parkinson's disease or as an adjunct therapy in more advanced cases.
Synonyms: (1R)-N-propargylindan-1-amine, (R)-N-2-Propynyl-1-indanamineCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates